SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors weigh an upbeat delivery report and raised production guidance against the dilution concerns of a significant public share offering. While some participants express frustration over the timing of the capital raise, the community is actively debating the stock's future liquidity, the strategic funding of factory expansion, and the long-term potential of the upcoming R2 vehicle line.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as institutional interest builds around its potential to lead the psychedelic medicine sector, further fueled by favorable government policy shifts and anticipation of upcoming Phase 3 trial data. Investors are closely monitoring the stock's clinical milestones and commercialization strategy, with many in the community expressing strong conviction in the companys first-mover advantage and long-term valuation potential.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing heavy selling pressure as semiconductor stocks undergo a sharp rotation, with investors debating whether the current decline represents a temporary pullback in the AI growth narrative or a structural shift in the sector. Community sentiment is deeply divided, with many traders aggressively scaling into the dip to capitalize on anticipated rebounds, while others warn of further downside and decaying leverage risks as market participants brace for upcoming economic data.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is trending as investors focus on the potential for a major legal settlement with Pfizer following its recent deal with Moderna and speculation regarding a future buyout. Community discussion remains heavily centered on the company's valuation, frustration over stalled share price momentum, and widespread criticism of the current C-suite's transparency and perceived influence by major shareholders.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean is trending as investors digest a strong earnings report that featured raised revenue guidance for 2026 and an optimistic 30% growth target for 2027, signaling a pivot toward higher-margin AI inference workloads. While some community members remain skeptical of the stock's valuation and potential dilution, bulls are pointing to the company's successful shift into enterprise-level scaling and rapid growth in AI-native customer revenue.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending following a massive $10 billion acquisition by Vertex Pharmaceuticals, with shares rallying significantly as the market digests the all-cash deal. Community discussion is focused on the premium valuation, the successful exit for long-term holders, and speculation regarding which rare-disease biotech might be the next target for similar big pharma consolidation.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions ($PENG) is rallying as investors gain confidence in its role as a specialized AI infrastructure integrator, following its recent designation as an NVIDIA AI Factory partner and the appointment of key leadership with deep industry connections. Community sentiment is heavily focused on the stock's potential for a valuation re-rating, with discussions highlighting its exposure to high-growth memory segments and its direct collaboration with major enterprise technology partners.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense downward price pressure and investor skepticism following its annual meeting, as shareholders express frustration over the lack of immediate revenue announcements and the decision to pause U.S. redomiciliation. Despite this, bulls remain focused on the company's 10x production scaling roadmap, significant cash reserves, and the potential of the Blazar hybrid laser to become an industry standard in high-bandwidth AI networks.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is capturing market attention following a massive $10 billion acquisition of Crinetics Pharmaceuticals, marking a significant strategic expansion into the endocrinology sector. The community is actively discussing the deal's premium valuation and Vertex's aggressive portfolio diversification, while also debating the long-term potential of the newly acquired pipeline assets like palsonify.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending as investors weigh strong earnings and guidance against a significant workforce reduction tied to a pivot toward an agentic AI-first operating model. The community is intensely debating whether these layoffs indicate a structural transformation that will drive long-term margin expansion or if the market is overreacting to cost-cutting measures during a period of high valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cancer Stocks That Are Advancing the Future of Oncology Care

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of +12.12% and +48.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -27.71% and -17.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy

Wall Street Zen raised Xilio Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.

Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8% - What's Next?

Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 4.8% - What's Next...

Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading Volume - Here's What Happened

Xilio Therapeutics (NASDAQ:XLO) Sees Strong Trading Volume - Here's Why...

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of tumor-activated immuno-oncology therapies for the treatment of cancer. The firm uses its Geographically Precise Solutions (GPS) platform to develop tumor-activated molecules, including cytokines, antibodies and other biologics. The company was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Xilio Therapeutics Inc

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.39
Prev Close	$9.44
Open	$9.39
Dividend Yield	0.00%
50-Day Moving Average	$8.36
Beta	0.82
Avg. Volume	36,093.78
PE Ratio	-2.58

52-Week High	$12.74
52-Week Low	$6.47
Market Capitalization	$62.07M
EPS (Annual)	-$4.19
Price to Book	0.75
Revenue Per Employee	$575,868.42

Feed

News

Sentiment

Fundamentals

Info

XLOXilio Therapeutics Inc

Latest XLO News